Aelis Farma SA (AELIS.PA)

14.14 0.00 (0.00%) As of 10:27AM CET. Market open.

Aelis Farma SA

146 rue Léo Saignat
Neurocentre Magendie
Bordeaux 33077
France
33 5 57 57 37 70
https://www.aelisfarma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 22

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Pier Vincenzo Piazza M.D., Ph.D.	CEO & Director	501.14k	N/A	1961
Ms. Marie Line Lefevre	Head of Fin.	N/A	N/A	N/A
Stephanie Monlezun	Chief Operating Officer	N/A	N/A	N/A
Ms. Lea Floquet	Head of Legal	N/A	N/A	N/A
Ms. Sandy Fabre	Head of Discovery & IP Leader	N/A	N/A	N/A
Ms. Aurelie Boucard	Head of Preclinical Devel.	N/A	N/A	N/A
Ms. Helle Mengel	Head of Clinical Devel.	N/A	N/A	N/A
Ms. Corinne Chaimbault	Head of Pharmaceutical Devel.	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Aelis Farma SA, a biotechnology company, engages in the research and development of treatments for brain diseases. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which completed Phase 1 clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is based in Bordeaux, France.

Corporate governance

Aelis Farma SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.